Selpercatinib, sold under the brand name Retevmo among others, is a targeted medication for the treatment of cancers in people whose tumors have an alteration (mutation or fusion) in a specific gene (RET which is short for "rearranged during transfection"). Before beginning treatment, the identification of a RET gene alteration must be determined using laboratory testing. Selpercatinib is taken by mouth.
Selpercatinib, sold under the brand name Retevmo among others, is a targeted medication for the treatment of cancers in people whose tumors have an alteration (mutation or fusion) in a specific gene (RET which is short for "rearranged during transfection"). Before beginning treatment, the identification of a RET gene alteration must be determined using laboratory testing. Selpercatinib is taken by mouth.
The most common side effects include changes in laboratory tests (including increased liver enzymes, increased blood sugar, decreased white cell and platelet counts, decreased protein level, decreased calcium, increased total cholesterol, increased creatinine, and decreased sodium) dry mouth, diarrhea, high blood pressure, fatigue, edema, rash, and constipation.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).